Overview of TEAEs in the overall population
| Overall, N = 103 . | Any grade, n (%) . | Grade ≥3, n (%) . |
|---|---|---|
| Any AE | 103 (100.0) | 97 (94.2) |
| Serious AE | 76 (73.8) | 54 (52.4) |
| AE leading to treatment discontinuation | 36 (35.0) | 30 (29.1) |
| AEs in ≥15% of patients | ||
| Hematologic AEs | ||
| Thrombocytopenia∗ | 75 (72.8) | 61 (59.2) |
| Neutropenia† | 67 (65.0) | 59 (57.3) |
| Anemia‡ | 61 (59.2) | 44 (42.7) |
| Infections§ | 74 (71.8) | 30 (29.1) |
| COVID-19|| | 30 (29.1) | 11 (10.7) |
| CRS¶ | 54 (52.4) | 1 (1.0) |
| Diarrhea | 48 (46.6) | 5 (4.9) |
| Nausea | 41 (39.8) | 2 (1.9) |
| Fatigue | 36 (35.0) | 7 (6.8) |
| Hypokalemia | 32 (31.1) | 9 (8.7) |
| Pyrexia | 30 (29.1) | 0 |
| Increased alanine aminotransferase | 29 (28.2) | 10 (9.7) |
| Increased aspartate aminotransferase | 26 (25.2) | 6 (5.8) |
| Peripheral neuropathy | 26 (25.2) | 1 (1.0) |
| Cough | 21 (20.4) | 0 |
| Hypomagnesemia | 20 (19.4) | 0 |
| Decreased appetite | 19 (18.4) | 3 (2.9) |
| Increased lipase | 19 (18.4) | 6 (5.8) |
| Injection-site reaction# | 18 (17.5) | 0 |
| Dyspnea | 17 (16.5) | 2 (1.9) |
| Constipation | 16 (15.5) | 0 |
| AEs of special interest | ||
| CRS¶ | 54 (52.4) | 1 (1.0) |
| ICANS | 3 (2.9) | 1 (1.0) |
| Clinical tumor lysis syndrome | 0 | 0 |
| Overall, N = 103 . | Any grade, n (%) . | Grade ≥3, n (%) . |
|---|---|---|
| Any AE | 103 (100.0) | 97 (94.2) |
| Serious AE | 76 (73.8) | 54 (52.4) |
| AE leading to treatment discontinuation | 36 (35.0) | 30 (29.1) |
| AEs in ≥15% of patients | ||
| Hematologic AEs | ||
| Thrombocytopenia∗ | 75 (72.8) | 61 (59.2) |
| Neutropenia† | 67 (65.0) | 59 (57.3) |
| Anemia‡ | 61 (59.2) | 44 (42.7) |
| Infections§ | 74 (71.8) | 30 (29.1) |
| COVID-19|| | 30 (29.1) | 11 (10.7) |
| CRS¶ | 54 (52.4) | 1 (1.0) |
| Diarrhea | 48 (46.6) | 5 (4.9) |
| Nausea | 41 (39.8) | 2 (1.9) |
| Fatigue | 36 (35.0) | 7 (6.8) |
| Hypokalemia | 32 (31.1) | 9 (8.7) |
| Pyrexia | 30 (29.1) | 0 |
| Increased alanine aminotransferase | 29 (28.2) | 10 (9.7) |
| Increased aspartate aminotransferase | 26 (25.2) | 6 (5.8) |
| Peripheral neuropathy | 26 (25.2) | 1 (1.0) |
| Cough | 21 (20.4) | 0 |
| Hypomagnesemia | 20 (19.4) | 0 |
| Decreased appetite | 19 (18.4) | 3 (2.9) |
| Increased lipase | 19 (18.4) | 6 (5.8) |
| Injection-site reaction# | 18 (17.5) | 0 |
| Dyspnea | 17 (16.5) | 2 (1.9) |
| Constipation | 16 (15.5) | 0 |
| AEs of special interest | ||
| CRS¶ | 54 (52.4) | 1 (1.0) |
| ICANS | 3 (2.9) | 1 (1.0) |
| Clinical tumor lysis syndrome | 0 | 0 |
Thrombocytopenia includes hematopoietic thrombocytopenia using the Standardized Medical Dictionary for Regulatory Activities Query narrow search.
Neutropenia includes neutropenia and decreased neutrophil count.
Anemia includes anemia, decreased hematocrit, decreased hemoglobin, decreased red blood cell count, and decreased serum ferritin.
Infections and infestations by system organ class.
COVID-19 includes COVID-19, COVID-19 pneumonia, and post–acute COVID-19 syndrome.
CRS is shown twice (as an AE in ≥15% of patients and as an AE of special interest).
Injection-site reaction includes injection-site reactions as high-level group terms.